Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned a consensus recommendation of “Buy” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $45.14.

A number of equities research analysts have recently weighed in on DNTH shares. Wedbush lowered their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price on the stock. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Finally, Oppenheimer initiated coverage on shares of Dianthus Therapeutics in a report on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 target price on the stock.

Dianthus Therapeutics Stock Up 2.3 %

Shares of DNTH stock opened at $29.41 on Thursday. The business has a 50-day moving average price of $27.72 and a two-hundred day moving average price of $26.43. Dianthus Therapeutics has a 12-month low of $6.58 and a 12-month high of $33.77. The firm has a market cap of $863.77 million, a P/E ratio of -5.31 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The firm had revenue of $1.86 million for the quarter, compared to the consensus estimate of $0.63 million. As a group, research analysts expect that Dianthus Therapeutics will post -2.28 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. SG Americas Securities LLC purchased a new stake in Dianthus Therapeutics in the second quarter worth $112,000. The Manufacturers Life Insurance Company purchased a new stake in Dianthus Therapeutics in the second quarter worth $236,000. WINTON GROUP Ltd purchased a new stake in Dianthus Therapeutics in the second quarter worth $265,000. Point72 DIFC Ltd purchased a new stake in Dianthus Therapeutics in the second quarter worth $334,000. Finally, Virtu Financial LLC purchased a new position in Dianthus Therapeutics during the first quarter valued at $390,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.